Park Medical earned a reputation as a pioneer in digital gammacamera design when it entered the market in 1993 with its Isocamline of systems. This year, the Lachine, Quebec, vendor intendsto reinforce its stature as an engineering innovator with a
Park Medical earned a reputation as a pioneer in digital gammacamera design when it entered the market in 1993 with its Isocamline of systems. This year, the Lachine, Quebec, vendor intendsto reinforce its stature as an engineering innovator with a radicallydifferent approach to high-energy radioisotope imaging.
With the rest of the industry embracing coincidence imagingof FDG-SPECT, Park has chosen to cast its lot with modified codedaperture technology (MCAT), according to CEO Richard Mullen. MCATwas developed by Dr. Harry Barratt at the University of Arizonain Tucson in the 1980s, but was set aside as impractical untilPark's chief scientist, Daniel Gagnon, took a second look at thetechnology.
The technique promises 10-fold improvement in sensitivity anda two-fold improvement in resolution over today's best gamma cameras,Mullen said. MCAT is less expensive than coincidence detectionand works with standard radiopharmaceutical and high-energy radioisotopes.Park will show phantom images produced with this investigationaltechnology.
The company will also feature a new infrared sensitivity contouringdevice available with its Isocam gamma cameras. Software enhancementson Park's Sun UltraSparc workstation will be emphasized as well.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.